This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Elevation Oncology’s 8K filing here.
About Elevation Oncology
Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Read More
- Five stocks we like better than Elevation Oncology
- What is a Bond Market Holiday? How to Invest and Trade
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- The Risks of Owning Bonds
- MarketBeat Week in Review – 01/13 – 01/17
